A placebo-controlled trial of intranasal growth hormone-releasing hormone [GHRH(1-44)-NH2] administration in normal young adults.

Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults.

Intranasal administration of neostigmine potentiates both intravenous and intranasal growth hormone (GH)-releasing hormone-induced GH release in short children.

Dose-effect study of intranasal administration of growth hormone-releasing hormone-44-NH2 in healthy subjects.

Development of responsiveness of young normal rats to growth hormone.

Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults.

Supplemental growth hormone increases the tumor cytotoxic activity of natural killer cells in healthy adults with normal growth hormone secretion.

The growth hormone releasing hormone (GHRH) response to a mixed meal is blunted in young adults with insulin-dependent diabetes mellitus whereas the somatostatin response is normal.

Prolonged elevation of luteinizing hormone (LH) after intranasal administration of an analog of LH-releasing hormone.

Long-term growth hormone treatment in growth hormone deficient adults.

[Quality of life of young adults after a growth hormone therapy with childhood onset].

Plasma gonadotropin and gonadotropin-releasing hormone levels after intranasal administration of gonadotropin releasing hormone.

Intranasal administration of medications.

Acute clonidine administration potentiates spontaneous diurnal, but not nocturnal, growth hormone secretion in normal short children.

Altered growth hormone response after growth hormone releasing hormone administration in chronic renal failure.

Role of growth hormone-releasing hormone on pentagastrin-induced growth hormone release in normal subjects.

Evaluation of the growth-hormone-releasing hormone test in short normal and growth-hormone-deficient children.

Growth hormone response to acute growth hormone releasing hormone administration in uraemic patients on haemodialysis.

Health-Related Quality of Life of Young Adults Treated with Recombinant Human Growth Hormone during Childhood.

The growth hormone deficiency syndrome in adults.

The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration.

Chronic growth hormone administration does not suppress endogenous growth hormone secretion in patients with neurosecretory growth hormone dysfunction.

Intranasal administration of butorphanol benefits old patients undergoing H-uvulopalatopharyngoplasty: a randomized trial.

Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects.

Digital ranges of motion: normal values in young adults.

Suggest Documents

Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults.

Intranasal administration of neostigmine potentiates both intravenous and intranasal growth hormone (GH)-releasing hormone-induced GH release in short children.

Dose-effect study of intranasal administration of growth hormone-releasing hormone-44-NH2 in healthy subjects.

Development of responsiveness of young normal rats to growth hormone.

Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults.

Supplemental growth hormone increases the tumor cytotoxic activity of natural killer cells in healthy adults with normal growth hormone secretion.

The growth hormone releasing hormone (GHRH) response to a mixed meal is blunted in young adults with insulin-dependent diabetes mellitus whereas the somatostatin response is normal.

Prolonged elevation of luteinizing hormone (LH) after intranasal administration of an analog of LH-releasing hormone.

Long-term growth hormone treatment in growth hormone deficient adults.

[Quality of life of young adults after a growth hormone therapy with childhood onset].

Plasma gonadotropin and gonadotropin-releasing hormone levels after intranasal administration of gonadotropin releasing hormone.

Intranasal administration of medications.

Acute clonidine administration potentiates spontaneous diurnal, but not nocturnal, growth hormone secretion in normal short children.

Altered growth hormone response after growth hormone releasing hormone administration in chronic renal failure.

Role of growth hormone-releasing hormone on pentagastrin-induced growth hormone release in normal subjects.

Evaluation of the growth-hormone-releasing hormone test in short normal and growth-hormone-deficient children.

Growth hormone response to acute growth hormone releasing hormone administration in uraemic patients on haemodialysis.

Health-Related Quality of Life of Young Adults Treated with Recombinant Human Growth Hormone during Childhood.

The growth hormone deficiency syndrome in adults.

The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration.

Chronic growth hormone administration does not suppress endogenous growth hormone secretion in patients with neurosecretory growth hormone dysfunction.

Intranasal administration of butorphanol benefits old patients undergoing H-uvulopalatopharyngoplasty: a randomized trial.

Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects.

Digital ranges of motion: normal values in young adults.

A placebo-controlled trial of intranasal growth hormone-releasing hormone [GHRH(1-44)-NH2] administration in normal young adults.

Recommend Documents

Follow Us